-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|April 1, 2024

Disparities in Access to Care for Ph+ ALL patients

The panel discusses disparities in the quality of care received by Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.


Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.